Mascarenhas, J., Harrison, C., Bose, P., Kiladjian, J., Lucchesi, A., Vannucchi, A., Mudge-Riley, M., Riggs, J., Peng, L., Huang, F., Wan, Y., Rodolf, V., Ho, J., Navada, S. C., Komrokji, R. S. (2025). IMpactMF, randomized, open-label, phase 3 trial of imetelstat (IME) versus best available therapy (BAT) in patients (pts) with intermediate-2 (INT-2) or high-risk (HR) myelofibrosis (MF) relapsed or refractory (R/R) to Janus kinase inhibitors (JAKi).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps6588